Sionna Therapeutics (NASDAQ:SION) Sets New 1-Year Low After Analyst Downgrade

Sionna Therapeutics, Inc. (NASDAQ:SION)’s stock price hit a new 52-week low during trading on Monday after BTIG Research downgraded the stock from a buy rating to a neutral rating. The stock traded as low as $4.01 and last traded at $4.50, with a volume of 38338161 shares traded. The stock had previously closed at $51.04.

A number of other research firms also recently commented on SION. Wall Street Zen downgraded Sionna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Freedom Capital cut Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 20th. Royal Bank Of Canada raised Sionna Therapeutics from an “underperform” rating to a “sector perform” rating and set a $5.00 price target for the company in a research note on Monday. Raymond James Financial lowered shares of Sionna Therapeutics from a “strong-buy” rating to a “market perform” rating in a research report on Monday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Sionna Therapeutics currently has a consensus rating of “Hold” and an average target price of $42.22.

Insider Buying and Selling

In related news, Director Orbimed Advisors Llc sold 85,918 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total value of $3,854,281.48. Following the sale, the director owned 2,469,959 shares of the company’s stock, valued at approximately $110,802,360.74. This represents a 3.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 85,918 shares of the stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $44.86, for a total value of $3,854,281.48. Following the sale, the director owned 2,469,959 shares in the company, valued at approximately $110,802,360.74. This trade represents a 3.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 403,726 shares of company stock worth $18,259,354. 5.10% of the stock is owned by corporate insiders.

Sionna Therapeutics News Summary

Here are the key news stories impacting Sionna Therapeutics this week:

• Positive Sentiment: Royal Bank of Canada upgraded Sionna from “underperform” to “sector perform” and assigned a $5.00 price target, while Stifel maintained a “hold” rating with a $7.00 target. These targets remain above the reported $4.50 share price, suggesting some analysts see potential for recovery. Analyst rating actions
• Neutral Sentiment: Wedbush reaffirmed its “neutral” rating with a $5.00 target, and Guggenheim reaffirmed its “neutral” view. The ratings indicate limited near-term conviction despite targets above the current share price. Analyst rating actions
• Negative Sentiment: Sionna reported topline results from two nucleotide binding domain 1 stabilizer programs targeting cystic fibrosis. Unfavorable clinical data led the company to discontinue SION-719, removing a key development program and weakening the investment case for its cystic fibrosis pipeline. Sionna discontinues cystic fibrosis drug
• Negative Sentiment: Multiple firms reduced their ratings following the trial update: BTIG moved from “buy” to “neutral,” Raymond James cut its view from “strong buy” to “market perform,” and Citizens JMP downgraded Sionna from “market outperform” to “market perform.” The coordinated downgrades reinforce investor concern about the clinical setback. Analyst downgrades
• Negative Sentiment: The sharp decline and unusually heavy trading activity also prompted Johnson Fistel to announce an investigation into potential securities-law violations. The investigation does not establish wrongdoing but adds reputational and legal uncertainty. Johnson Fistel investigation

Institutional Trading of Sionna Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in Sionna Therapeutics in the 2nd quarter valued at about $64,875,000. Deutsche Bank AG purchased a new stake in shares of Sionna Therapeutics during the second quarter worth about $2,347,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Sionna Therapeutics during the second quarter worth about $44,000. Bank of New York Mellon Corp acquired a new position in shares of Sionna Therapeutics in the second quarter valued at approximately $1,829,000. Finally, State of Wyoming acquired a new position in shares of Sionna Therapeutics in the second quarter valued at approximately $35,000.

Sionna Therapeutics Stock Performance

The firm’s 50 day moving average is $41.62 and its 200-day moving average is $40.17.

Sionna Therapeutics (NASDAQ:SION) last released its earnings results on Thursday, August 6th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.02). As a group, research analysts forecast that Sionna Therapeutics, Inc. will post -2.63 EPS for the current fiscal year.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.